Menu Search
Equities

Innovative Pharmaceutical Biotech Ltd

399:HKG.HS

Innovative Pharmaceutical Biotech Ltd

Actions
  • Price (HKD)0.199
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change-0.50%
  • Beta--
Data delayed at least 15 minutes, as of May 31 2024.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Innovative Pharmaceutical Biotech Limited is a Hong Kong-based investment holding company principally engaged in pharmaceuticals and biotechnology businesses. The Company operates through five segments. Genetic Testing Services segment is engaged in the provision of genetic testing services in the People’s Republic of China (PRC) and Hong Kong. Bio-Industrial Products segment is engaged in the distribution of bio-industrial products in the PRC. Beauty Equipment and Products segment is engaged in the trading of beauty equipment and products in Hong Kong. Securities Investment segment is engaged in securities investment in Hong Kong and outside Hong Kong. Research and Development segment is engaged in the research, development and commercialization of the oral insulin products.

  • Revenue in HKD (TTM)7.66m
  • Net income in HKD63.65m
  • Incorporated2013
  • Employees20.00
  • Location
    Innovative Pharmaceutical Biotech LtdRoom 2111, West Tower, Shun Tak Centre168-200 Connaught RoadSheung Wan Hong KongHKG
  • Phone+852 25986818
  • Fax+852 25986628
  • Websitehttp://www.ipb.asia
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.